Monoamine transporters (Norepinephrine, dopamine, and serotonin transporters) (MATs)

The norepinephrine, dopamine, and serotonin transporters (NET, DAT, and SERT) are integral membrane proteins belonging to the solute carrier family 6 (SLC6) that play a critical role in regulating neurotransmission within the central nervous system (Kristensen et al., 2011). These transporters are responsible for the reuptake of their respective monoamine neurotransmitters from the synaptic cleft back into the presynaptic neuron, effectively terminating the signal and maintaining neurotransmitter homeostasis (Iversen, 2006). Dysregulation of these transport systems is strongly linked to the pathophysiology of various mental health disorders, including major depressive disorder, attention deficit hyperactivity disorder (ADHD), and obesity (Skolnick et al., 2003). Drugs that target these transporters, such as triple reuptake inhibitors (TRIs), aim to increase the extracellular concentrations of all three monoamines to alleviate symptoms of depression and improve cognitive focus (Marks et al., 2008). While dual inhibitors like SNRIs are common, targeting all three transporters is a strategy intended to produce a more rapid and robust antidepressant response (Liang et al., 2008). However, the inclusion of dopamine transporter inhibition introduces specific challenges, such as the potential for substance abuse and increased cardiovascular stimulation (Prinssen et al., 2002). These transporters are also the primary targets for several psychostimulants and older antidepressants, highlighting their central role in neuropsychopharmacology (StatPearls, 2023).

Other names

Monoamine transportersNET, DAT, and SERTMonoamine reuptake pumpsSLC6A2, SLC6A3, and SLC6A4Triple reuptake inhibitor targets

Inhibition of the presynaptic reuptake of norepinephrine, dopamine, and serotonin, leading to increased synaptic availability and prolonged signaling of these neurotransmitters.